Theranostics on molecular machine action driven by the Cherenkov light

2019 Fiscal Year Final Research Report

• Project/Area Number: 18K19412
• Research Category: Grant-in-Aid for Challenging Research (Exploratory)
• Allocation Type: Multi-year Fund
• Review Section: Medium-sized Section 47:Pharmaceutical sciences and related fields
• Research Institution: Osaka University of Pharmaceutical Sciences
• Principal Investigator: Temma Takashi 大阪薬科大学, 薬学部, 教授 (90378787)
• Co-Investigator(Kenkyū-buntansha): 近藤 直哉 大阪薬科大学, 薬学部, 助教 (80756172) ; 平田 雅彦 大阪薬科大学, 薬学部, 講師 (00268301)
• Project Period (FY): 2018-06-29 – 2020-03-31
• Keywords: 分子マシン / 18F-FDG / セラノスティクス

Outline of Final Research Achievements

In this study, we focused on the possibility that the Cherenkov light produced by 18F-FDG could act as a driving force for molecular machine to damage tumor cells. We thus designed and synthesized a new cancer-targeting molecular machine and evaluated a cytotoxicity in cancer cells. We demonstrated high potential of a bicyclic peptide for targeting integrin expressed in tumors among several peptide candidates tested. We also synthesized the bicyclic peptide modified molecular machine successfully. Furthermore, we demonstrated a cytotoxicity of the modified molecular machine in vitro.

Free Research Field

放射性薬品化学

Academic Significance and Societal Importance of the Research Achievements

本研究課題は、本邦で月間3万人以上が対象となる18F-FDG PET検査によるがん診断の後、速やかに分子マシン駆動がん治療を直結させる方法論の開発にかかる挑戦的原理構築研究である。チェレンコフ光を生じる18Fと細胞傷害性を有する分子マシンが共局在するがん部位においてのみ治療効果を発現することから、従来法よりも高い有効性と安全性が期待される。本研究成果は、今後のがんセラノスティクスの推進に重要な知見を与えうる。